Biological
GLIDE
GLIDE is a biological therapy with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph not_applicable
2
50%
Ph phase_2
1
25%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Other(2)
Detailed Status
unknown2
Recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
N/A2 (50.0%)
Trials by Status
recruiting125%
completed125%
unknown250%
Recent Activity
1 active trials
Showing 4 of 4
recruitingnot_applicable
Regulatory Clearance of the Glide Control Strategy for Upper Limb Prostheses
NCT06539936
completednot_applicable
Clinical Evaluation of Silk'n Glide for Face
NCT02103608
unknownphase_1
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
NCT03091933
unknownphase_2
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
NCT03154918
Clinical Trials (4)
Showing 4 of 4 trials
NCT06539936Not Applicable
Regulatory Clearance of the Glide Control Strategy for Upper Limb Prostheses
NCT02103608Not Applicable
Clinical Evaluation of Silk'n Glide for Face
NCT03091933Phase 1
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
NCT03154918Phase 2
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4